TinyGemsBreaks Archive - Page 12 of 121

FridaySep 06, 2024 9:59 am

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, provided a strategic letter from outgoing CEO Chris Bunka updating all stakeholders. In the strategic update, Bunka discussed Lexaria’s performance in the capital markets; the company’s Phase 1b DehydraTECH-CBD hypertension trial and Australian-registered Phase 1b DehydraTECH-GLP-1 diabetes and weight-loss study; ongoing R&D; and his reason for stepping aside from his role as CEO. “It is because of the combination of events that include our successful money-raising, our R&D success, our new relationship with one pharmaceutical company and continued pursuit of others, and our confidence in our strategic direction…

ThursdaySep 05, 2024 2:31 pm

TinyGemsBreaks – Reliant Coffee Named to the 2024 Inc. 5000 List of Fastest Growing Companies

Reliant Coffee, the leading provider of premium B2B automated bean-to-cup coffee subscription services, is announcing that it has been named to the Inc. 5000 class of 2024, debuting at #271 among all companies. Reliant Coffee was ranked 14th in the Food and Beverage category and 32nd among Florida companies. An exclusive ranking of the country’s fastest-growing private companies, the 2024 Inc. 5000 list represents companies that have posted rapid revenue growth amid inflationary pressure, the rising costs of capital, and hiring challenges. “We are honored to debut at number 271 on the Inc. 5000 list of fastest growing companies,” commented…

ThursdaySep 05, 2024 11:16 am

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of Richard Christopher as the new CEO, effective August 31, 2024. Mr. Christopher is a recognized industry veteran with over three decades of experience in the medical device and pharmaceutical industries. He has domestic and international experience in leadership, operations, acquisitions/licensing, business development, strategic planning and capital markets. Mr. Christopher takes over from outgoing CEO, Chris Bunka, who has stepped aside from the role. Mr. Bunka remains as the Chairman of the Board of Directors and has been appointed Executive Strategic Advisor to the…

WednesdaySep 04, 2024 3:25 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Slated to Present at H.C. Wainwright 26th Annual Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in the upcoming H.C. Wainwright 26th Annual Global Investment Conference. The event is slated for Sept. 9–11, 2024, in New York. According to the announcement, CEO John Climaco will present at the event; his presentation will be available as an on-demand video webcast beginning Sept. 9 at 7 a.m. ET. Climaco will also be available to participate in one-on-one meetings. To view the on-demand webcast, visit https://ibn.fm/gaP8o To view the full…

TuesdaySep 03, 2024 12:25 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has entered into a Materials Transfer Agreement with a pharmaceutical company. Under the terms of the agreement, the pharmaceutical company will evaluate Lexaria’s DehydraTECH(TM) technology in a pre-clinical setting. Lexaria will be responsible for formulating and supplying certain DehydraTECH compositions, with the pharmaceutical company evaluating the pharmacokinetics of these compositions in animal studies. According to the company, Lexaria has awarded the pharmaceutical company a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination. The work is expected to be completed within roughly 6 months…

FridayAug 30, 2024 2:45 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) BayMedica Poised as Rare Cannabinoids Drive Market Growth

InMed Pharmaceuticals’ (NASDAQ: INM) subsidiary BayMedica is positioned amid a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique properties and potential health benefits, driving significant market growth. The company published a report on the expansion of the minor cannabinoid market in 2023. “The report, based on data from Headset, the largest industry dataset, explores the growth, competition and consumer trends in ten regulated states, encompassing 85 million of the 158 million residents in areas where recreational cannabis is legal,” reads a recent article. “The report highlights a 5.4% revenue increase in the edible market,…

ThursdayAug 29, 2024 12:07 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test Results

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting that the tolerability and additional pharmacokinetic (“PK”) results from its human pilot study #2, GLP-1-H24-2, have been received. According to the results, absorption improvements appear to continue with DehydraTECH-processed Rybelsus(R) vs. Rybelsus tablets, even under “fed” conditions. The results also show that DehydraTECH-treated Rybelsus does absorb through a mouth-melt product format. “We were pleased to find that none of the nine people taking the DehydraTECH-processed Rybelsus swallowed as a capsule experienced any adverse events whatsoever,” the company stated in the press release. “However, of the nine human…

ThursdayAug 29, 2024 11:36 am

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Subsidiary Expands National Dealer Network Westward with 20 Locations

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is announcing that its subsidiary, Bollinger Motors, has added TEC Equipment, Inc. to its sales and service network. The move, which adds 20 select sales and service locations, expands the subsidiary’s commercial EV dealer network across all key markets in the Western United States. The new TEC dealers are in Arizona (Phoenix), California (Dixon, Fontana, La Mirada, Lathrop, Oakland, San Diego and San Francisco), Iowa (Sioux City), Nebraska (Omaha), Nevada (Las Vegas and Reno), Oregon (Eugene, Medford, Portland, Redmond and Wilsonville), South Dakota (Sioux Falls) and Washington (Lacey and Seattle).…

TuesdayAug 27, 2024 2:04 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, is announcing receipt of the first results from human pilot study #2, GLP-1-H24-2. According to the announcement, the company’s DehydraTECH(R)-processed Rybelsus(R) evidenced a trend toward higher overall absorption under fed conditions compared to Rybelsus(R) that was not processed with DehydraTECH. The DehydraTECH-processed Rybelsus(R) evidenced higher semaglutide levels in 17 of the 19 blood draws taken until the 24-hour completion of the study, averaging 18.8% higher semaglutide levels over the course of the study compared to Rybelsus(R) alone. However, the announcement noted that the differences were variable and not…

TuesdayAug 27, 2024 1:17 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that CEO John Climaco will present and discuss recent corporate events at the upcoming LIVE! with Webull Corporate Connect: Virtual Biotech Investor Webinar. The presentation is scheduled for Wednesday, August 28, 2024, at 3:20 p.m. ET. To register for the live webinar, visit https://ibn.fm/JXz89 To view the full press release, visit https://ibn.fm/GfqLq About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks